#CMPS↓

CMPS/ 01/07/2026 · 7:25 AM

Compass Pathways Advances PTSD Treatment and Prepares for Depression Launch

Compass Pathways receives FDA approval to begin late-stage PTSD trials with COMP360 psilocybin treatment while preparing for potential 2026 launch for treatment-resistant depression.

CMPS/ 12/10/2025 · 6:29 AM

Oppenheimer Upgrades Compass Pathways on Growing Confidence in COMP360

Oppenheimer upgrades Compass Pathways to Outperform with a $15 target, citing rising conviction that COMP360 psilocybin therapy could become the first FDA-approved psychedelic treatment for depression.